Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: Meta-analysis

World Journal of Gastroenterology

Volumn 19, Issue 39, 2013, Pages 6665-6678

  Ye, Xiao Guang ^a   Su, Qi Min ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Decompensated cirrhosis; Entecavir; Hepatitis B; Lamivudine; Meta analysis; Randomized controlled trial

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; BILIRUBIN; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ARTICLE; CHILD TURCOTTE PUGH SCORE; DECOMPENSATED LIVER CIRRHOSIS; DIARRHEA; FATIGUE; FOLLOW UP; HEADACHE; HEPATITIS B; HUMAN; HYPERSOMNIA; INCIDENCE; INSOMNIA; META ANALYSIS; MORTALITY; NAUSEA; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

DECOMPENSATED CIRRHOSIS; ENTECAVIR; HEPATITIS B; LAMIVUDINE; META-ANALYSIS.; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTIVIRAL AGENTS; BILIRUBIN; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GUANINE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LIVER CIRRHOSIS; MIDDLE AGED; ODDS RATIO; PROTHROMBIN TIME; SERUM ALBUMIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84886882616     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i39.6665     Document Type: Article

References (32)

1. Chi ZC. Antiviral therapy of chronic hepatitis B with liver cirrhosis. Zhongxiyi Jiehe Ganbing Zazhi 2006; 16: 129-132
2. Schiff E, Simsek H, Lee WM, Chao YC, Sette H, Janssen HL, Han SH, Goodman Z, Yang J, Brett-Smith H, Tamez R. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008; 103: 2776-2783 [PMID: 18721244 DOI: 10.1111/j.1572-0241.2008.02086.x]
3. Realdi G, Fattovich G, Hadziyannis S, Schalm SW, Almasio P, Sanchez-Tapias J, Christensen E, Giustina G, Noventa F. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1994; 21: 656-666 [PMID: 7814813 DOI: 10.1016/S0168-8278(94)80115-0]
4. Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991; 13: 627-631 [PMID: 2010157 DOI: 10.1002/hep.1840130403]
5. Huang Y, Wu H, Wu S, Fu D, Ma Y, Shen X. A meta-analysis of nucleos(t)ide analogues in patients with decompensated cirrhosis due to hepatitis B. Dig Dis Sci 2013; 58: 815-823 [PMID: 23053891]
6. Chinese Society of Infctious Diseases, Parasitic Epidemiology and Hepatology. China guidelines for HBV management. Zhonghua Ganranbing Zazhi 2005; 23: 421-431
7. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12 [PMID: 8721797 DOI: 10.1016/0197-2456(95)00134-4]
8. Feng J, Dou F, Su J, Li P, Lun YX. Effect of antiretroviral therapy to hepatitis B cirrhosis. Zhongguo Shiyong Yixue 2008; 3: 13-14
9. Yang J, Fan HZ. Virologic response of multiple nucleoside analogues therapy to patients with hepatitis B decompensated cirrhosis. Linchuang Luntan 2012; 14: 83-84
10. Shen CS. Effect of entecavir for treatment of 40 patients with active hepatitis B decompensated cirrhosis. Linchuang Guancha 2011; 30: 376-377
11. Huang ZG, Liu J, Xu YP. Entecavir therapy in patients with decompensated HBV-related cirrhosis. Chuanranbing Xinxi 2009; 22: 112-114
12. Chen FZ, Li GQ, Zhang L, Liu HY. Clinical effect of entecavir in patients with decompensated hepatitis B cirrhosis. Linchuang Gandanbing Zazhi 2010; 26: 608-612
13. Li CP, Deng LN, Hou HB, Wang QL. Effect of entecavir in patients with hepatitis B cirrhosis. Yinanbing Zazhi 2011; 10: 211-212
14. Shao JB, Xu J, Zhu DL, Dai WW. Clinical Observation of Entecavir in the Treatment of Decompensated Cirrhotic Patient with HBV for 96 Weeks. Zhongguo Yiyao Zhinan 2010; 8: 11-13
15. Kong ZF. Efficacy analysis of entecavir in patients with hepatitis B cirrhosis. Jiankang Bidu Zazhi 2011; 9: 78
16. Hyun JJ, Seo YS, Yoon E, Kim TH, Kim DJ, Kang HS, Jung ES, Kim JH, An H, Kim JH, Yim HJ, Yeon JE, Lee HS, Byun KS, Um SH, Kim CD, Ryu HS. Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis. Liver Int 2012; 32: 656-664 [PMID: 22099071 DOI: 10.1111/ j.1478-3231.2011.02676.x]
17. Wang GL, Wen JB, Wen P, Qiu P, Gong M, Han M. Costeffectiveness Analysis of 4 Pharmacotherapeutic Schemes for Decompensated Hepatic Cirrhosis Secondary to Chronic Hepatitis B. Yaowu Jingjixue 2012; 23: 3169-3171
18. Yang JH, Zheng S, You LY, Tang YM, Liu H. Therapeutic effects of 48-week entecavir treatment in patients with decompensated cirrhosis caused by hepatits B virus. Shiyong Ganzangbing Zazhi 2012; 15: 407-410
19. Zhou WX, Lu GL, Liu X. Clinical efficacy ananlysis of nucleoside analogs in the treatment of hepatitis B virus related decompensated cirrhosis. Zhongguo Shenghua Yaowu Zazhi 2012; 33: 170-172
20. Liu XL, Zhu JF, Li WL, Xu RR, Wu MS. Clinical analysis of nucleosis drugs used in treatment of liver cirrhosis after hepatitis B. Dangdai Yixue 2013; 19: 100-101
21. Wang JL, Wang B. Clinical epidemiology: Clinical scientific research and design, measure and evaluation. Shanghai: Shanghai Kexue Jishu Chubanshe, 2009
22. Chien RN, Lin CH, Liaw YF. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol 2003; 38: 322-327 [PMID: 12586298 DOI: 10.1016/S0168-8278(02)00419-1]
23. Tsubota A, Arase Y, Suzuki Y, Suzuki F, Sezaki H, Hosaka T, Akuta N, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kumada H. Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol 2005; 20: 426-432 [PMID: 15740488 DOI: 10.1111/ j.1440-1746.2004.03534.x]
24. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-696 [PMID: 12627352 DOI: 10.1086/368083]
25. Osborn M. Safety and efficacy of entecavir for the treatment of chronic hepatitis B. Infect Drug Resist 2011; 4: 55-64 [PMID: 21694909 DOI: 10.2147/IDR.S4188]
26. Hou JL. Entecavir: New choice of the treatment for patient with HBV. Ganzang 2005; 10: 164-166
27. Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52: 176-182 [PMID: 20006394 DOI: 10.1016/ j.jhep.2009.11.007]
28. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-893 [PMID: 20683932 DOI: 10.1002/hep.23785]
29. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686 [PMID: 16530509 DOI: 10.1053/j.gastro.2005.11.016]
30. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73 [PMID: 16391218 DOI: 10.1001/ jama.295.1.65]
31. Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, Jacobson IM, Lim SG, Naoumov N, Marcellin P, Piratvisuth T, Zoulim F. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5: 890-897 [PMID: 17632041 DOI: 10.1016/j.cgh.2007.05.004]
32. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, Boron-Kaczmarska A, Martin P, Goodman Z, Colonno R, Cross A, Denisky G, Kreter B, Hindes R. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 2039-2049 [PMID: 16762627 DOI: 10.1053/j.gastro.2006.04.007]